85Q Stock Overview
Provides digital chronic condition management solutions for employers and health plans. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Trellus Health plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.0005 |
| 52 Week High | UK£0.049 |
| 52 Week Low | UK£0.0005 |
| Beta | 0.15 |
| 11 Month Change | 0% |
| 3 Month Change | -83.33% |
| 1 Year Change | -98.80% |
| 33 Year Change | -99.92% |
| 5 Year Change | n/a |
| Change since IPO | -99.93% |
Recent News & Updates
Recent updates
Shareholder Returns
| 85Q | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.1% | -1.5% |
| 1Y | -98.8% | 18.0% | 7.9% |
Return vs Industry: 85Q underperformed the German Healthcare industry which returned 18% over the past year.
Return vs Market: 85Q underperformed the German Market which returned 7.9% over the past year.
Price Volatility
| 85Q volatility | |
|---|---|
| 85Q Average Weekly Movement | 49.4% |
| Healthcare Industry Average Movement | 3.9% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 85Q's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 85Q's weekly volatility has increased from 36% to 49% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 31 | Marla Dubinsky | www.trellushealth.com |
Trellus Health plc provides digital chronic condition management solutions for employers and health plans. The company offers TrellusElevate, a proprietary HIPAA-compliant technology platform to coordinate and deliver personalized care remotely through telemedicine. Its platform provides patients with access to a care team, educational content resources, and remote monitoring capabilities for the treatment of inflammatory bowel diseases, which include the chronic incurable conditions of Crohn's Disease and ulcerative colitis.
Trellus Health plc Fundamentals Summary
| 85Q fundamental statistics | |
|---|---|
| Market cap | €1.30m |
| Earnings (TTM) | -€6.29m |
| Revenue (TTM) | €51.91k |
25.1x
P/S Ratio-0.2x
P/E RatioIs 85Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 85Q income statement (TTM) | |
|---|---|
| Revenue | US$55.00k |
| Cost of Revenue | US$0 |
| Gross Profit | US$55.00k |
| Other Expenses | US$6.72m |
| Earnings | -US$6.66m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.041 |
| Gross Margin | 100.00% |
| Net Profit Margin | -12,114.55% |
| Debt/Equity Ratio | 0% |
How did 85Q perform over the long term?
See historical performance and comparison